Navigation Links
Drug Found Ineffective Against Lung Disease
Date:6/30/2009

People with idiopathic pulmonary fibrosis gain no survival benefit, research finds,,

MONDAY, June 29 (HealthDay News) -- Treatment with interferon gamma-1b (Ifn-g1b) does not improve survival in people with a fatal lung disease called idiopathic pulmonary fibrosis, according to a study that was halted early after no benefit to participants was found.

Previous research had suggested that Ifn-g1b might benefit people with idiopathic pulmonary fibrosis, particularly those with mild to moderate disease.

The new study included 826 people, ages 40 to 79, who lived in Europe and North America. They were given injections of either 200 micrograms of Ifn-g1b (551 people) or a placebo (275) three times a week.

After a median of 64 weeks, 15 percent of those in the Ifn-g1b group and 13 percent in the placebo group had died. Symptoms such as flu-like illness, fatigue, fever and chills were more common among those in the Ifn-g1b group than in the placebo group. The two groups had similar rates of serious side effects, the researchers found.

"We cannot recommend treatment with interferon gamma-1b since the drug did not improve survival for patients with idiopathic pulmonary fibrosis, which refutes previous findings from subgroup analyses of survival in studies of patients with mild-to-moderate physiological impairment of pulmonary function," Dr. Talmadge E. King Jr., of the University of California, San Francisco, and colleagues wrote in the study published online and in an upcoming print issue of The Lancet.

The negative findings of this study "should be regarded as definite, [but] they should not discourage patients to participate in one of the several clinical trials currently underway to find effective treatments for this devastating disease," Dr. Demosthenes Bouros, of the Democritus University of Thrace in Greece, wrote in an accompanying editorial.

Bouros added that people deemed suitable "should be enrolled early in the transplantation list, which is today the only mode of treatment that prolongs survival."

More information

The U.S. National Heart, Lung and Blood Institute has more about idiopathic pulmonary fibrosis.



-- Robert Preidt



SOURCE: The Lancet, news release, June 29, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Sudden Cardiac Arrest Foundation Mourns the Loss of Michael Jackson
2. The AGA Foundation awards grant to Dr. Michael Choi to further his research on carcinoid tumors
3. New piece found in colorectal cancer puzzle
4. AUA Foundation announces 2009 Research Scholar Program award winners
5. AUA Foundation names the 2009 Astellas Rising Stars in Urology award winners
6. Jennifer Dodson, M.D., named 2009 AUA Foundation/NIDDK/NCI Surgeon-Scientist Award winner
7. The Crohns & Colitis Foundation and Procter & Gamble Pharmaceuticals Announce 2009 Celebrating UC Success Contest Winners
8. Elizabeth Edwards to Deliver Keynote Address at Patient Advocate Foundations 10th Annual Patient Congress
9. Virtuosant Technology Offers Virtuosant Foundation Portal™ for Free
10. The United Nations Foundation Joins White House Initiative to Encourage Public Service
11. Children's National Medical Center Honors The Children's Cancer Foundation for Commitment to Area Kids
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Found Ineffective Against Lung Disease
(Date:10/13/2017)... , ... October 13, 2017 , ... ... the certification process to promote standards of excellence for the field of eating ... for March 22 – 25, 2018 in Orlando, Florida at the Omni Resort ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized health ... expanded their existing home health joint venture through an agreement, effective October 1, ... joint venture home health company with Asante, delivering clinically integrated care, for the ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Texas , Oct. 11, 2017  True ... services, has amplified its effort during National Breast ... about hereditary cancer risks. ... of Clinical Oncology calculated that more than 10 ... have inherited mutations in BRCA1 or BRCA2 and have ...
(Date:10/10/2017)... 10, 2017  NDS received FDA 510(k) clearance in May 2017 ... display stand specifically designed for endoscopy environments. An innovative secondary monitor ... clinical solution to support the improvement of patient outcomes, procedural efficiency, ... ... ...
(Date:10/7/2017)... IRVING, Texas , Oct. 6, 2017   ... industry with more than $100 billion in purchasing power, ... industry news and information. The Newsroom is ... chain and industry trends, infographics, expert bios, news releases, ... Besides having access to a wealth of resources at ...
Breaking Medicine Technology: